Cardiogenic shock management January 14 th, 2016 10h30-12h.

Slides:



Advertisements
Similar presentations
September 29,2010 Karen Harkness RN CCNC PhD. Definition Not a clinical diagnosis Heart failure is a complex syndrome in which abnormal heart function.
Advertisements

Heart Failure (CHF) Brunner, ch. 30, pp
Assisted Circulation MEDICAL MEDICAL  Drugs  EECP MECHANICAL  IABP ( Introaortic balloon pump)  VAD (Ventricular assist device)
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
By: ABDULRAHMAN ALSALMI INTRA AORTIC BALLOON PUMP CHIEF CARDIAC PERFUSIONIST KFMMC.
SHOCK.
Cardiogenic Shock and Hemodynamics. Outline Overview of shock – Hemodynamic Parameters – PA catheter, complications – Differentiating Types of Shock Cardiogenic.
Can we prevent myocardial and renal revascularization injury? Preventive effect of trimetazidine MR on myocardial and renal injury in diabetic patients.
Left Ventricular Assist Devices: The What and the Who Lance E. Sullenberger MD FACC FACP Capital Cardiology Associates.
Bio-Med 350 Complications of Acute M.I. Douglas Burtt, M.D.
Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC.
Management of Acute Shock and Right Ventricular Failure Nader Moazami, MD Department of Thoracic and Cardiovascular Surgery and Biomedical Engineering,
Ventricular Assist Devices Brian Schwartz, CCP February 25, 2003.
ST-Elevation Myocardial Infarction & Cardiogenic Shock - What Should We Do? Advanced Angioplasty 2008 Dan Blackman Leeds General Infirmary.
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH.
Intra-Aortic Balloon Pump Counterpulsation
Current Management of Heart Failure GP clinical update 17 th June 2015 Dr Raj Bilku Consultant Cardiologist Clinical Lead Cardiology QEH.
Causes Myocardial dysfunction eg IHD, CM Volume overload eg AR, MR Obstruction eg AS, HCM Diastolic dysfunction eg Constriction Mechanical problems eg.
Indication and contra-indications for cardiac catheterization
Dr. Adel El Banna M.D Consultant of Cardiac Surgery Head of Cardiac Surgery Department National Heart Institute.
Cardiogenic shock Kasia Hryniewicz, M.D. Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, MN Greater Twin Cities Area Chapter of.
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
Medical Progress: Heart Failure. Primary Targets of Treatment in Heart Failure. Treatment options for patients with heart failure affect the pathophysiological.
Cardio Investigations. Patients presenting with chest pain may be identified as having definite or possible angina from their history alone. Risk Factor.
Complications of Acute M.I.
Revascularizaton of Ischemic DCM Percutaneous Revascularization and Hemodynamic Support Matthew R. Wolff, M.D. University of Wisconsin Disclosures: Cordis.
Optimal Therapies for End-Stage Thoracic Organ Failure: The Critical Role of the Surgeon and the Use of ECMO, MCS and Transplantation Decision Making:
Cardiogenic Shock Dr. Belal Hijji, RN, PhD October 12 & 15, 2011.
Circulatory Failure - Shock. Case Presentation 56 year old man with a past history of type 2 diabetes and hypertension. Presented to the ER with a 12.
HEART FAILURE Jamil Mayet Consultant Cardiologist.
MYOCARDIAL INFARCTION. CASE 1 Mr. A: 38 years old He smokes 1 pack of cigarettes per day He has no other past medical history 8 hours ago, he gets sharp.
 Introduction  Classification of inotropes  Postoperative myocardial dysfunction.  Choice of inotrope  Indications in specific settings.
AB 1/03 Non-Coronary Intervention Circulatory Support Advanced Angioplasty 2003 Andreas Baumbach Bristol Royal Infirmary.
Cardiac assistance: role of haemodynamics January 14 th, h30-10h.
Ihab Alomari, MD, FACC Assistant professor – Interventional Cardiology University of California, Irvine Division of Cardiology Cath Lab Essentials : LV.
Types of Hemodynamic Support in the Cath Lab.
Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.
Heart Failure J. Lynn Davis, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April 25, 2015.
Dr.K.Alizadeh. Assistant Professor of Cardiac Surgery Dr.M.Tabari. Assistant Professor of Anesthesiology Ghaem hospital,Mashad University of Medical Science.
Patient Selection & Risk Stratification Soltani GH, MD.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Congestive Heart Failure Dory Roedel Ferraro, DNP, ANP-BC, CBN.
Conflict of Interest Baxter Research Grant Medtronic Research Grant
Device Navigation Leaflet Capture Distal tip Saddle CAUTION: Investigational Device Limited by Federal (United States) Law to Investigational Use.
Pharmacotherapy Of Cardiovascular Disorders: Heart Failure
Transcatheter interatrial shunt device (IASD)
Contemporary Approaches to Acute Mechanical Circulatory Support
Management of Cardiogenic Shock in AMI
Drugs used for Congestive Heart Failure
Improving Outcomes in Cardiogenic Shock
University of Chicago Medicine
Myocarditis.
Nat. Rev. Cardiol. doi: /nrcardio
Giuseppe Tarantini MD, PhD
Nasim Naderi M.D. Cardiologist June 2011
Figure 1 Diagnostic flowchart for patients with suspected heart failure—showing alternative ‘echocardiography first’ (blue) or ‘natriuretic peptide first’
The Use of Impella for CGS Patients Does It Save Lives?
Cardiogenic Shock Cardiology Clinics
A Hard Look at Cardiogenic Shock: IABP-SHOCK II Revisited
Mechanical Circulatory Support Devices HOSEIN PASANDI.
Zoll Firm Lecture Series
Nat. Rev. Cardiol. doi: /nrcardio
Juan J. Russo et al. JACC 2019;73:
Definition and Classification of Shock
Pericarditis Inflammation of the pericardium Many causes
The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.
Effect of methylprednisolone versus placebo on the risk of acute kidney injury: subgroup analysis by preoperative chronic kidney disease. Effect of methylprednisolone.
Changes in clinical parameters and use of catecholamines during hospitalisation (A) inotropic score, B) serum lactate levels and (C) SAPS II from baseline.
Presentation transcript:

Cardiogenic shock management January 14 th, h30-12h

About the aetiologies of cardiogenic shock, which proposition(s) is/are correct? A) Myocardial infarction is responsible for ≈ 40% B) Myocardial infarction is responsible for ≈ 75% C) The 2 nd leading cause is pulmonary embolism D) The 2 nd leading cause is acute myocarditis E) The ischemic aetiology has decreased from 50% in 30 years

About the aetiologies of cardiogenic shock, which proposition(s) is/are correct? A) Myocardial infarction is responsible for ≈ 40% B) Myocardial infarction is responsible for ≈ 75% C) The 2 nd leading cause is pulmonary embolism D) The 2 nd leading cause is acute myocarditis E) The ischemic aetiology has decreased from 50% in 30 years

What is/are the predictive factor(s) of poor prognosis in cardiogenic shock? A) Diabetes B) Renal insufficiency C) Older age D) Use of vasopressors and inotropes E) Atrial fibrillation onset

What is/are the predictive factor(s) of poor prognosis in cardiogenic shock? A) Diabetes B) Renal insufficiency C) Older age D) Use of vasopressors and inotropes E) Atrial fibrillation onset

Mortality of cardiogenic shock: A) Is ≈ 45% B) Is ≈ 20% C) Has decreased over the past 20 years D) Is higher in case of non ischemic versus ischemic cause E) Is mostly due to liver failure

Mortality of cardiogenic shock: A) Is ≈ 45% B) Is ≈ 20% C) Has decreased over the past 20 years D) Is higher in case of non ischemic versus ischemic cause E) Is mostly due to liver failure

About Serelaxin, which of the following proposition(s) is/are correct? A) Is a recombinant form of the human Relaxin hormone B) Serelaxin is produced during a normal pregnancy C) Is a potent vasodilator D) Has major diuretic effects E) Has shown improved survival in acute heart failure with reduced LVEF

About Serelaxin, which of the following proposition(s) is/are correct? A) Is a recombinant form of the human Relaxin hormone B) Serelaxin is produced during a normal pregnancy C) Is a potent vasodilator D) Has major diuretic effects E) Has shown improved survival in acute heart failure with reduced LVEF

About Ularitide, which of the following proposition(s) is/are correct? A) Is a myosin activator B) Is a synthetic analogous of the human natriuretic peptide urodilatin C) His main target is in the renal collecting tubules D) Could decrease renin-angiotensinaldosterone system (RAAS) activation E) TRUE-AHF is a phase III multicentre randomised clinical trial evaluating the efficacy and safety of Ularitide

About Ularitide, which of the following proposition(s) is/are correct? A) Is a myosin activator B) Is a synthetic analogous of the human natriuretic peptide urodilatin C) His main target is in the renal collecting tubules D) Could decrease renin-angiotensinaldosterone system (RAAS) activation E) TRUE-AHF is a phase III multicentre randomised clinical trial evaluating the efficacy and safety of Ularitide

What is/are the ventricular assistance device(s) that can be used in cardiogenic shock? A) Intra-Aortic Balloon Pump (IABP) B) The Impella C) The TandemHeart system D) veno-venous ECMO E) Veno-arterial ECMO

What is/are the ventricular assistance device(s) that can be used in cardiogenic shock? A) Intra-Aortic Balloon Pump (IABP) B) The Impella C) The TandemHeart system D) veno-venous ECMO E) Veno-arterial ECMO

Which of the following proposition(s) is/are contra-indication(s) to ECMO? A) Severe Mitral regurgitation B) Severe aortic regurgitation C) Intracardiac thrombus D) On going sepsis E) Severe Right ventricular dysfunction

Which of the following proposition(s) is/are contra-indication(s) to ECMO? A) Severe Mitral regurgitation B) Severe aortic regurgitation C) Intracardiac thrombus D) On going sepsis E) Severe Right ventricular dysfunction